Nine patients with acute leukaemia developed a complex syndrome of hypocalcaemia and hypomagnesaemia during treatment. These metabolic abnormalities developed rapidly in some patients and gave rise to acute symptoms. Immunoreactive parathormone concentrations in these patients were found to be either absolutely or inappropriately low.
among subjects sampled in 1976 at the age of 18 years who had received Salk vaccine. The authors attributed the decline in the proportion with antibodies to the waning of immunity to poliovirus after oral vaccine.
Thus evidence from various sources suggests that a cohort of children born in the middle 1960s has proportionately fewer circulating antibodies than those who are older or younger. In our view this is associated with a decline in the vaccination rates together with the interruption of vaccine courses brought about by changes from inactivated to oral vaccine and confusion over the number of doses needed. This does not rule out a possible waning in immunity after oral vaccine but does suggest that this may not be the only cause. The existence of this cohort of children, who are not so well protected as the rest of the population and who might contract poliomyelitis if they travel abroad or come in close contact with vaccinated babies who are excreting the virus, highlights the need for a complete course of vaccine or for a booster dose to be given at or around schoolleaving age.
Introduction
Hypokalaemia and hyponatraemia are recognised complications of acute leukaemia, particularly during treatment. ' We recently observed that very low plasma concentrations of calcium and magnesium are also common in patients with acute leukaemia during chemotherapy. These metabolic abnormalities present considerable management problems.
Patients and methods
During a nine-month period nine patients (eight female, one male; age range 10-81 years) undergoing intensive chemotherapy and radiotherapy including bone-marrow transplantation developed profound hypocalcaemia resulting in tetany in four. Before treatment all had been normocalcaemic and normomagnesaemic and had had normal renal function. Six of the patients had acute myeloblastic leukaemia (including two with acute myelofibrosis) and three acute lymphoblastic leukaemia (two T-cell, one common).
Eight of the nine patients had been resistant to or had relapsed from previous chemotherapy and had been referred for experimental treatment. At the time of onset of hypocalcaemia all were receiving their second or subsequent course of chemotherapy. Three of the patients had undergone allogeneic bone-marrow transplantation and thus had been exposed to total body irradiation and high-dose cyclophosphamide. Seven of the patients were receiving non-absorbable antibiotics (neomycin, colistin) for gastrointestinal decontamination and oral antifungal agents. All patients also received prophylactic co-trimoxazole.
All the patients suffered from moderate to severe vomiting and diarrhoea. Nutritional state measured by weight loss (>10% body weight) was substantial in seven patients. None of the nine patients, however, had received parenteral nutrition.
Chemotherapeutic agents common to all nine patients were an anthracycline antibiotic (doxorubicin in eight and daunorubicin in one) and cytarabine. Six patients also received thioguanine. Other agents used in some but not all were etoposide, 2'deoxycoformycin, colaspase, vindesine, mAMSA, and methotrexate.
During the study period seven patients had proved bacterial septicaemia, which was treated with empirical aminoglycosides, intravenous penicillins, intravenous antifungal agents, and metronidazole. They were also receiving frusemide regularly because of sodium overload secondary to some of these antibiotics. A smaller number of patients required other intravenous agents, including four patients who had received acyclovir treatment.
At the time of development of the hypocalcaemia we measured plasma concentrations of magnesium and immunoreactive parathyroid hormone (iPTH) (N-terminal assay).
Results
Plasma calcium and magnesium concentrations-All nine patients became hypocalcaemic from three to 60 days (mean 30 days) after the start of treatment (table) . Renal function remained normal. Hypocalcaemia and hypomagnesaemia worsened in five of the patients, with a lowest recorded corrected plasma concentration of calcium of 1-3 mmol/l (5 36 mg/100 ml) and of magnesium of 0 28 mmol/l (0-68 mg/100 ml). In two of these patients who were available for follow-up serum iPTH concentration was persistently low. Eight of the nine patients had plasma magnesium concentrations that were either reduced or at the lower limit of the normal reference range; the ninth patient had a normal plasma magnesium concentration. 7 Another mechanism that may contribute to hypocalcaemia in these patients is the secretion of calcitonin or a similar peptide that may suppress mobilisation of calcium from the bone. 8 These patients had non-detectable, low, or only marginally raised iPTH concentrations in association with, in some cases, very low calcium concentrations: this is an unusual association.
In a series of patients with osteomalacia even minimally low calcium concentrations were associated with appreciably raised iPTH concentrations (unpublished observations). Thus our patients had either absolute or "relative" hypoparathy-I 0 a roidism, which must have contributed to the pathogenesis of hypocalcaemia. The hyposecretion of iPTH in these patients is probably secondary to several factors including hypomagnesaemia, which inhibits the secretion of iPTH both in vivo and in vitro.29 Antimicrobial and cytotoxic drugs may also have an inhibitory effect on iPTH secretion. Vinblastine, for instance, disrupts the morphology of the parathyroid gland.10 Aminoglycosides have been incriminated in the pathogenesis of hypoparathyroidism,3 but in our series two patients developed the syndrome in the absence of aminoglycoside treatment. All nine patients, however, had been taking doxorubicin (or daunorubicin) and cytarabine; these drugs may have contributed to the suppression of parathyroid secretion.
In conclusion, we have described a syndrome that consists of a combination of hypocalcaemia, hypomagnesaemia, and a state of absolute or relative hypoparathyroidism in patients receiving treatment for acute leukaemia. In our series the syndrome was common and led to profound clinical problems, including tetany. The condition appears to be multifactorial and requires further investigation. Awareness of this metabolic problem allowed us to intervene therapeutically and to reduce morbidity. We subsequently prevented any appreciable decrease in plasma calcium and magnesium concentrations by giving appropriate supplements and lcx-hydroxycholecalciferol. Despite this concentrations of parathyroid hormone remained low (unpublished data).
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